Status:
COMPLETED
Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome
Lead Sponsor:
WellSpan Health
Conditions:
Lynch Syndrome
Endometrial Cancer
Eligibility:
FEMALE
18-99 years
Brief Summary
Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial can...
Detailed Description
This is an observational cohort study. Tissue specimens obtained that have been labeled with the diagnosis of endometrial hyperplasia will be identified and their chart reviewed for demographic date o...
Eligibility Criteria
Inclusion
- Appropriate specimen, hysterectomy or biopsy with final labeled diagnosis of endometrial hyperplasia of any grade
Exclusion
- Any specimen that is later associated with endometrial cancer in subsequent pathology exam
Key Trial Info
Start Date :
May 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 2 2023
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT05257057
Start Date
May 8 2019
End Date
June 2 2023
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WellSpan
York, Pennsylvania, United States, 17403